MedTrace Logo

Ondansetron Versus Domperidone for Treating Vomiting in Acute Gastroenteritis in Children

NCT05076461 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-10-13

No results posted yet for this study

Summary

Most of the trials conducted comparing ondansetron and domperidone have been conducted among children aged below 5 or 6 years of age while no study from Pakistan has compared efficacy of these antiemetic agents among children up to 12 years of age. The findings of present study will give valuable evidence about the effectiveness of these antiemetic agents to prevent vomiting among children suffering with acute gastroenteritis at a resource limited setting of South Punjab, Pakistan.

Conditions

  • Vomiting in Infants and/or Children
  • Acute Gastroenteritis

Interventions

DRUG

Ondansetron

Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight

Sponsors & Collaborators

  • Tehsil Headquarter Hospital

    lead OTHER_GOV

Principal Investigators

  • Tauseef Ahmad, MBBS · Tehsil Headquarter Hospital, Liaquatpur, Pakistan.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05076461 on ClinicalTrials.gov